Clinical Research
Cardiac Resynchronization Therapy
Reduction of the Risk of Recurring Heart Failure Events With Cardiac Resynchronization Therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

https://doi.org/10.1016/j.jacc.2011.04.024Get rights and content
Under an Elsevier user license
open archive

Objectives

The evaluation of the risk of recurring heart failure events (HFEs) was a pre-specified substudy of MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).

Background

There are limited data regarding the effect of cardiac resynchronization therapy with a defibrillator (CRT-D) on the occurrence of recurring heart failure episodes after a first post-implantation HFE.

Methods

Data with regard to recurring HFEs were prospectively collected for all 1,820 MADIT-CRT participants. The CRT-D versus defibrillator-only risk for nonfatal first- and subsequent-HFEs was assessed by Cox proportional hazards and Andersen-Gill proportional intensity regression modeling, respectively, in efficacy analyses recognizing active device-type during follow-up.

Results

Multivariate analysis showed that CRT-D was associated with a significant reduction in the risk of a first HFE (hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.44 to 0.67, p < 0.001) and with a similar magnitude of reduction in the risk of HFEs subsequent to a first post-enrollment event (HR: 0.62, 95% CI: 0.45 to 0.85, p = 0.003). The benefit of CRT-D for the prevention of first and subsequent HFEs was pronounced among patients with left bundle branch block (HR: 0.38, 95% CI: 0.29 to 0.49, p < 0.001; and HR: 0.50, 95% CI: 0.33 to 0.76, p = 0.001, respectively) and nonsignificant in non-left bundle branch block patients (HR: 1.12, 95% CI: 0.77 to 1.64, p = 0.55; and HR: 0.99, 95% CI: 0.58 to 1.69, p = 0.96, respectively; p values for interaction: p < 0.001 and p = 0.06, respectively). The occurrences of first and second HFEs were associated with 7- and nearly 19-fold respective increases in the risk of subsequent mortality.

Conclusions

In the MADIT-CRT trial, the benefit of cardiac resynchronization therapy for the reduction in recurring HFEs was maintained after the occurrence of a first post-enrollment event. The occurrence of HFEs greatly increased the risk of death. (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271)

Key Words

cardiac resynchronization therapy
heart failure
mortality

Abbreviations and Acronyms

CI
confidence interval
CRT
cardiac resynchronization therapy
CRT-D
cardiac resynchronization therapy-defibrillator
HFE
heart failure event
HR
hazard ratio
ICD
implantable cardioverter-defibrillator
ITT
intention to treat
LBBB
left bundle branch block
NYHA
New York Heart Association

Cited by (0)

The MADIT-CRT trial was supported by a research grant from Boston Scientific Corp., St. Paul, Minnesota, to the University of Rochester School of Medicine and Dentistry. Drs. Moss, Hall, and Zareba have received research support for the conduct of the MADIT-CRT trial from Boston Scientific through a grant to the University of Rochester. All other authors have reported that they have no relationships to disclose. Drs. Goldenberg and Hall contributed equally to this work.